SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$45.53 USD
+1.33 (3.01%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $45.55 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SWTX 45.53 +1.33(3.01%)
Will SWTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SWTX
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
SWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug
SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data
Wall Street Analysts Think SpringWorks Therapeutics (SWTX) Could Surge 212%: Read This Before Placing a Bet
Other News for SWTX
SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
SpringWorks Therapeutics -- Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024